PCN65 THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+ METASTATIC BREAST CANCER

Abstract

Under current reimbursement (CR) practice, although an add-on medicine in a combination therapy may produce marginal value in terms of health gain, the original therapy may also share in the reward for this additional value. We examine a “marginal value-based reimbursement” (MVBR) model in which an add-on therapy can fully obtain its marginal value. Our aim was to evaluate the impact of MVBR model on effective price (EP) and value-based price (VBP) of an add-on therapy, as compared to CR model. We used the addition of pertuzumab to trastuzumab and docetaxel (PHT) for human epidermal growth factor receptor 2 positive metastatic breast cancer as a case study.